Incretin mimetics and receptor agonists investigated for modulating gastric motility, hypothalamic satiety signaling, and systemic energy expenditure.
The seminal STEP 1 clinical trial demonstrating average weight reductions of 14.9% in the semaglutide group versus 2.4% with placebo at 68 weeks.
Multinational phase 3 trial establishing substantial and sustained body-weight reductions of up to 20.9% with dual GIP/GLP-1 receptor co-agonist tirzepatide.
Landmark phase 2 trial published in the New England Journal of Medicine demonstrating unprecedented weight reduction of up to 24.2% over 48 weeks with the GIP/GLP-1/Glucagon triple agonist retatrutide.
The landmark SELECT trial establishing a statistically significant 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic patients treated with once-weekly semaglutide.
Head-to-head phase 3 trial demonstrating that the dual GIP/GLP-1 receptor co-agonist tirzepatide achieved superior glycemic control and weight reduction compared to semaglutide 1 mg.
Head-to-head phase 3 trial demonstrating that the dual GIP/GLP-1 receptor co-agonist tirzepatide achieved superior glycemic control and weight reduction compared to semaglutide 1 mg.
Pivotal phase 3 clinical trial demonstrating that the stabilized GHRH analog tesamorelin selectively reduces pathological visceral abdominal adipose tissue by 15.2% without subcutaneous fat wasting.
Clinical toxicology trial confirming that the fat-mobilizing peptide fragment AOD-9604 exhibits high tolerability in humans without inducing growth-hormone-like insulin resistance or elevating IGF-1.
